Organon & Co (OGN)
15.31
-0.30
(-1.92%)
USD |
NYSE |
Nov 14, 16:00
15.31
0.00 (0.00%)
After-Hours: 20:00
Organon Cash and Short Term Investments (Quarterly): 763.00M for Sept. 30, 2024
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 763.00M |
| June 30, 2024 | 704.00M |
| March 31, 2024 | 575.00M |
| December 31, 2023 | 693.00M |
| September 30, 2023 | 414.00M |
| June 30, 2023 | 326.00M |
| March 31, 2023 | 459.00M |
| December 31, 2022 | 706.00M |
| Date | Value |
|---|---|
| September 30, 2022 | 499.00M |
| June 30, 2022 | 545.00M |
| March 31, 2022 | 694.00M |
| December 31, 2021 | 737.00M |
| September 30, 2021 | 1.008B |
| June 30, 2021 | 730.00M |
| March 31, 2021 | 141.00M |
| December 31, 2020 | 12.00M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
12.00M
Minimum
Dec 2020
1.008B
Maximum
Sep 2021
562.88M
Average
634.00M
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Eli Lilly and Co | 3.518B |
| ResMed Inc | 426.36M |
| Ligand Pharmaceuticals Inc | 219.64M |
| TG Therapeutics Inc | 341.04M |
| Sage Therapeutics Inc | 569.15M |